Literature DB >> 11990526

Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma.

Amyn M Rojiani1, Lingyun Li, Leroy Rise, Dietmar W Siemann.   

Abstract

Combretastatin A4 disodium phosphate (CA4DP) was evaluated in a xenograft model of AIDS-KS. KS xenografts were highly vascular, showing brisk mitotic activity, focal areas of necrosis, and intervening fibrovascular septae. Neoplastic cells were large or spindle-shaped, with vesicular nuclei and modest pleomorphism. Multiple junctions, microvillous-like projections, abortive lumina and rare Weibel Palade bodies were revealed by electron microscopy. Treatment with CA4DP (100 mg/kg) resulted in rapid onset of vascular effects that within 4 h resulted in an almost complete vascular shutdown in these tumors. Histological evaluation showed morphological damage within a few hours after treatment, followed by extensive necrosis which increased to approximately 90% by 24 h. At this time, viable tumor cells were evident only at the periphery of the tumor. These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11990526     DOI: 10.1080/028418602317314136

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Authors:  Lori Rice; Christine Pampo; Sharon Lepler; Amyn M Rojiani; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2010-10-23       Impact factor: 3.514

2.  Leukemia regression by vascular disruption and antiangiogenic therapy.

Authors:  Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

3.  Monitoring the treatment efficacy of the vascular disrupting agent CA4P.

Authors:  Beth A Salmon; Howard W Salmon; Dietmar W Siemann
Journal:  Eur J Cancer       Date:  2007-04-23       Impact factor: 9.162

4.  Characterizing the tumor response to treatment with combretastatin A4 phosphate.

Authors:  Beth A Salmon; Dietmar W Siemann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

5.  Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

Authors:  Dietmar W Siemann; Wenyin Shi
Journal:  Anticancer Res       Date:  2008 Jul-Aug       Impact factor: 2.480

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.